sST2 as a value-added biomarker in heart failure
- 31 October 2019
- journal article
- review article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 501, 120-130
- https://doi.org/10.1016/j.cca.2019.10.029
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- A combined index of cardiac biomarkers as a risk factor for early cardiovascular mortality in hemodialysis patientscclm, 2013
- Soluble ST2 protein in chronic heart failure is independent of traditional factorsVideosurgery and Other Miniinvasive Techniques, 2013
- Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the communityEuropean Heart Journal, 2012
- Usefulness of Soluble Concentrations of Interleukin Family Member ST2 as Predictor of Mortality in Patients With Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection FractionThe American Journal of Cardiology, 2011
- Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute DyspneaJournal of Invasive Cardiology, 2010
- Primary sources and immunological prerequisites for sST2 secretion in humansCardiovascular Research, 2010
- The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their RatioAmerican Journal of Clinical Pathology, 2010
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJournal of Invasive Cardiology, 2008
- The IL-33/ST2 pathway: therapeutic target and novel biomarkerNature Reviews Drug Discovery, 2008
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007